Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 3/20 | 0.72 |
| ▸ | TYK2 | P29597 | 14/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031714 | 0.85 | CSNK2B (0.56) | CSNK2BTYK2 | |
| SCHEMBL2031718 | 0.85 | CSNK2B (0.56) | CSNK2BTYK2 | |
| SCHEMBL2031716 | 0.85 | CSNK2B (0.56) | CSNK2BTYK2 | |
| SCHEMBL2032300 | 0.84 | CSNK2B (0.52) | CSNK2BTYK2GSK3B | |
| SCHEMBL6926464 | 0.84 | CSNK2B (0.52) | CSNK2BTYK2GSK3B | |
| SCHEMBL2032303 | 0.84 | CSNK2B (0.52) | CSNK2BTYK2GSK3B | |
| SCHEMBL14242878 | 0.84 | CSNK2B (0.66) | CSNK2BTYK2 | |
| SCHEMBL15368817 | 0.84 | CSNK2B (1.00) | CSNK2BTYK2KCNN3 | |
| SCHEMBL15368338 | 0.81 | CSNK2B (0.84) | CSNK2BTYK2KCNN3 | |
| SCHEMBL14243119 | 0.80 | CSNK2B (0.47) | CSNK2BTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | CSNK2B 13/4885TYK2 63/4885GSK3B 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.